Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
No phase specified Educational/Counseling/Training, Supportive care Active 18 to 89 Pharmaceutical / Industry SMI-CHOL-82008
NCT00737399

Trial Description

Summary

Anxiety and depression have been found to be significant co-occurring conditions in cancer patients. This study examines these and other psychological conditions in patients diagnosed with cholangiocarcinoma, a rare cancer of the bile duct, with an average survival time of three to six months post-diagnosis. Participants are taught EFT in a telephone and internet group coaching session, prior to which they complete the SA-45, a 45 item questionnaire, and the ISI or Insomnia Severity Index. The SA-45 has nine subscales for such conditions as anxiety, depression, hostility and psychotism, as well as two primary scales to determine the breadth and severity of psychological distress. Self-assessed pain severity will also be measured on a Likert-type scale. The study is expected to enroll 10 to 15 cholangiocarcinoma patients, and use a within-subjects, time series, repeated measures design. Symptoms are assessed prior to coaching, after four, and again after eight weekly coaching sessions. It is hypothesized that a drop in the severity of co-occurring psychological symptoms, pain and insomnia may occur after EFT coaching.

Eligibility Criteria

Inclusion Criteria:

Diagnosis of Cholangiocarinoma

Ability to complete forms and attend phone coaching sessions

Exclusion Criteria:

None

Trial Contact Information

Trial Lead Organizations/Sponsors

Soul Medicine Institute

Dawson Church, PhD

Principal Investigator

Dawson Church, PhD		Ph: 707 237 6951
		Email: dawson@soulmedicine.net

Deburah Tribbey		Ph: 707 237 6951
		Email: deb@soulmedicine.net

Trial Sites

U.S.A.

California

Santa Rosa

Soul Medicine Institute

Dawson Church, PhD Ph: 707-237-6951

Email: dawson@soulmedicine.net

Deb Tribbey Ph: 707 237 6951

Email: deb@soulmedicine.net

Dawson Church, PhD Principal Investigator

See All Trial Sites

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00737399
Information obtained from ClinicalTrials.gov on March 18, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.